EHS
EHS

Dova, Salix partner to promote Doptelet for patients with liver disease

Dova Pharmaceuticals and Salix Pharmaceuticals entered into an exclusive agreement to promote Doptelet, according to a press release.
Doptolet (avatrombopag, Dova) is a recently FDA-approved treatment for thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
“Salix considers liver disease a strategic therapeutic area of focus,” Mark McKenna, president of Salix Pharmaceuticals, said in the release. “Adding Doptelet to our portfolio will enable our sales force to promote yet another innovative product that addresses a true unmet

Source link

EHS
Back to top button